ICSI has adopted a policy of transparency, disclosing potential conflict and competing interests of all individuals who participate in the development, revision and approval of ICSI documents (guidelines, order sets and protocols). This applies to all work groups (guidelines, order sets and protocols) and committees (Committee on Evidence-Based Practice, Cardiovascular Steering Committee, Women's Health Steering Committee, Preventive & Health Maintenance Steering Committee and Respiratory Steering Committee).
Participants must disclose any potential conflict and competing interests they or their dependents (spouse, dependent children, or others claimed as dependents) may have with any organization with commercial, proprietary, or political interests relevant to the topics covered by ICSI documents. Such disclosures will be shared with all individuals who prepare, review and approve ICSI documents.
John Beithon, MD jointly owns stock through a family member's employee benefit option.
Frederick Taylor, MD has participated and received remuneration as an Advisory Board member for
GlaxosmithKline and Merck. He received speaker's fees and associated expense compensation for Speaker's Bureau participation for GlaxoSmithKline, Merck and Endo Pharmaceuticals. He has also received honorarium from Current Medicine for editorship of Current Pain and Headache Reports for 2008 and 2009. Additionally, he receives authorship content fees from Up to Date.
Jerry Swanson, MD has received royalties from Up To Date.
No other work group members have potential conflicts of interest to disclose.